Inserm, U1048 and Université Toulouse III, I2MC, Toulouse 31432, France.
CHU de Toulouse, Laboratoire d'Hématologie, Toulouse 31059, France.
Int J Mol Sci. 2019 Jun 25;20(12):3111. doi: 10.3390/ijms20123111.
In women, oral menopausal hormonal therapy (MHT) is associated with adverse effects including an increased incidence of thromboembolic events, classically attributed to an increase in several liver-derived coagulation factors due to hepatic first pass. While platelets are central players in thrombus constitution, their implication in women treated with estrogens remains incompletely characterized. Platelets and their medullar progenitors, megakaryocytes, express estrogen receptors (ER) that may explain, at least in part, a sensitivity to hormonal changes. The purpose of this review is to summarize our current knowledge of estrogen actions on platelets and megakaryocytes in mice following in vivo administration and in women using MHT.
在女性中，口服绝经后激素治疗（MHT）与不良反应相关，包括血栓栓塞事件发生率增加，这通常归因于肝脏首过效应导致几种肝脏来源的凝血因子增加。虽然血小板是血栓形成的核心参与者，但它们在接受雌激素治疗的女性中的作用仍不完全清楚。血小板及其骨髓前体细胞巨核细胞表达雌激素受体（ER），这至少可以部分解释对激素变化的敏感性。本综述的目的是总结我们目前对体内给予雌激素后小鼠血小板和巨核细胞以及使用 MHT 的女性中雌激素作用的认识。
